Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;104(7):1302-1308.
doi: 10.3324/haematol.2018.208751. Epub 2019 Jun 20.

Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?

Katherine D Cummins  1 , Saar Gill  2
Affiliations

Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?

Katherine D Cummins et al. Haematologica. 2019 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A proposed design for a novel therapeutic platform for acute myeloid leukemia (AML), combining hematopoietic stem and progenitor cell (HSPC)-CD33KO with CD33-directed chimeric antigen receptor-modified T cell (CART33) therapy. CART33 manufacture is performed at steady state, prior to mobilization agents that may affect the composition of the resultant CART product. CART33 and HSPC-CD33KO will be from the same allogeneic donor. Sex difference between donor and patient are shown only to demonstrate an allogeneic donor for the purpose of this diagram. KO: knock-out. RR AML: relapsed/refractory AML; AlloCART-33: anti CD33 CAR T-cell, made from allogeneic donor cells; HSPC-CD33KO: hematopoietic stem/progeitor cells with CD33 knock-out; alloHSCT: allogeneic hematopoietic stem/progenitor cell transplant.
See this image and copyright information in PMC

References

    1. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439–448. - PMC - PubMed
    1. June CH, O’Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365. - PubMed
    1. Ritchie DS, Neeson PJ, Khot A, et al. Persistence and efficacy of second generation CAR-T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013;21(11):2122–2129. - PMC - PubMed
    1. Brenner MK. CAR T cells for acute myeloid leukemia: the LeY of the land. Mol Ther. 2013;21(11):1983–1984. - PMC - PubMed
    1. Ehninger A, Kramer M, Rollig C, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4:e218. - PMC - PubMed

MeSH terms

Substances